ArticleCureus2026
Clinical Outcomes of Early Antiviral Treatment for COVID-19 in a Japanese Long-Term Care Facility With Limited Resources: A Retrospective Study of 107 Residents.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background After COVID-19 was reclassified as a Class 5 infectious disease in Japan on May 8, 2023, long-term care facilities assumed primary responsibility for onsite management of infected residents. Detailed reports of clinical outcomes under this policy are scarce. SARS-CoV-2 infection remained clinically relevant despite repeated vaccination, including receipt of five or more vaccine doses in many residents, highlighting the need for early antiviral treatment in nursing home settings. Methods We conducted a retrospective observational study from May 8, 2023, to February 28, 2025, in a resource-limited Japanese long-term care facility. Among 113 residents diagnosed with COVID-19, six presented with moderate illness at diagnosis, operationally defined as decreased oxygen saturation with SpO₂ ≤ 93%, and were immediately referred to and admitted to the hospital. These residents were excluded from the primary analysis. The primary cohort comprised 107 residents with mild illness at diagnosis who received molnupiravir 800 mg twice daily for five days within eight hours of diagnosis. Outcomes included clinical progression, hospitalization after initiation of molnupiravir, mortality, and outbreak characteristics. Results Among the 107 treated residents, 104 were wheelchair-dependent, and three were bedridden. The mean age was 85.6 years, and 49 residents were aged ≥85 years. Prior COVID-19 vaccination was documented in 95 residents (88.7%). Eighty-three residents (77.5%) had documented receipt of at least five vaccine doses, whereas 24 residents (22.4%) had no documented receipt of at least five doses, including residents with zero to four recorded doses and those with unknown vaccination history. One resident (0.9%) deteriorated on day 3 despite early antiviral treatment, was hospitalized, and died after hospitalization. No in-facility deaths occurred. Six outbreak clusters were identified during the study period. Conclusions Early antiviral treatment for mild COVID-19 was feasible and associated with favorable outcomes in a resource-limited long-term care facility despite severe structural limitations, including multi-bedrooms and poor ventilation. These findings support rapid diagnosis, prompt molnupiravir initiation, and early hospital referral for residents with oxygen desaturation in frail older adults living in long-term care facilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.